Catalent has acquired therapy development company Promethera Biosciences’ cell therapy manufacturing subsidiary, Hepatic Cell Therapy Support SA (HCTS), including its 32,400 ft2 facility in Gosselies, Belgium. Under the terms of the agreement, the new facility will provide space for Catalent’s commercial-scale plasmid DNA (pDNA) manufacturing and service offering. The facility also features an existing cleanroom infrastructure, process development and quality control laboratories, and warehouse space. Source: Biopharm International 6/5/2021